Target intelligence / Profile preview

3-deoxy-D-manno-oct-2-ulosonic acid (KDO) biosynthetic pathway enzymes (KDO pathway enzymes)

Target
KDO pathway enzymes
Molecular classification
Enzyme
01

Overview

3-deoxy-D-manno-oct-2-ulosonic acid (KDO) biosynthetic pathway enzymes are a group of essential bacterial proteins responsible for the synthesis and activation of KDO, a unique eight-carbon sugar required for the assembly of lipopolysaccharides (LPS) in Gram-negative bacteria (Cipolla et al., 2010, PMID: 21114433). LPS is a fundamental component of the bacterial outer membrane, providing a robust physical barrier against antibiotics and host immune responses (UniProt, 2024). The pathway involves several key enzymes, including KDO-8-phosphate synthase (KdsA), KDO-8-phosphate phosphatase (KdsC), CMP-KDO synthetase (KdsB), and KDO transferase (WaaA), which collectively ensure the incorporation of KDO into the lipid A-core region (PubChem, 2024). Because KDO is essential for the viability of most Gram-negative pathogens and the pathway is entirely absent in humans, these enzymes are considered high-value targets for the development of novel, narrow-spectrum antibiotics (Cipolla et al., 2010). Inhibition of these enzymes leads to the production of truncated LPS or the complete failure of outer membrane assembly, resulting in bacterial cell death or extreme sensitization to other antimicrobial agents. While several potent inhibitors have been identified in research settings, such as KDO and CTP analogs, their clinical progression has been limited by challenges in penetrating the complex Gram-negative cell envelope (PMID: 19157056).

Other names
KDO-utilizing enzymesKDO biosynthetic pathway3-deoxy-D-manno-oct-2-ulosonic acid pathwayKDO metabolism enzymes2-keto-3-deoxy-octonate pathwayKdsA/KdsB/WaaA pathway
02

Mechanism of action

Inhibition of the biosynthesis or transfer of 3-deoxy-D-manno-oct-2-ulosonic acid (KDO), which prevents the assembly of functional lipopolysaccharides (LPS) and compromises the bacterial outer membrane.

03

Biological functions

Lipopolysaccharide biosynthesisCell wall organizationBacterial growthOuter membrane assembly
04

Disease associations

Infection
05

Safety considerations

Gram-negative membrane permeability (challenge for drug entry)Development of bacterial resistanceTarget specificity (though human homologs are absent)
06

Interacting drugs

2-phosphoglycolate (research inhibitor)

4 more in the full profile.

07

Biomarkers

Lipopolysaccharide (LPS) levelsKDO-8-phosphate accumulationBacterial growth inhibitionOuter membrane permeability

Beyond the preview

Go deeper on 3-deoxy-D-manno-oct-2-ulosonic acid (KDO) biosynthetic pathway enzymes (KDO pathway enzymes).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 3-deoxy-D-manno-oct-2-ulosonic acid (KDO) biosynthetic pathway enzymes (KDO pathway enzymes).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call